Explore the rising threat of ticks to pets and humans, and discover effective prevention strategies with Credelio Quattro (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets).
Sponsored by Elanco. Head to dvm360 Flex and login or create a free CE account and claim your credit after listening to this episode.
Program Description:
Ticks pose a significant health risk to companion animals, both as blood-feeding parasites and as vectors for numerous pathogens. Over the past few decades, tick populations have expanded and intensified due to factors such as increased globalization, greater movement of humans and animals, and climate change. In the United States, common tick species—including the blacklegged tick, lone star tick, American dog tick, and brown dog tick—have the potential to transmit a range of bacterial, protozoal, and viral pathogens.
Serological data indicate that tick-borne pathogens are a persistent challenge for dogs, with U.S. canines frequently testing positive for agents of anaplasmosis, Lyme disease, and ehrlichiosis. Many of these same ticks and pathogens also pose a public health risk, as the tick species that commonly bite dogs can also transmit these same pathogens to humans. As a result, dogs can serve as valuable sentinels for tick-borne disease risks of their human families.
Despite awareness of the risks ticks pose to pets, ticks are often and easily overlooked. Given that ticks are a year-round threat in most regions, annual testing and the routine use of fast-acting tick control products play a critical role in protecting pet health by killing ticks and reducing pathogen transmission risk.
Learning Objectives:
Credelio Quattro Indications & ISI.
Indications: Credelio Quattro is indicated for the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment and control of roundworm (immature adult and adult Toxocara canis and adult Toxascaris leonina), hookworm (fourth stage larvae, immature adult, and adult Ancylostoma caninum and adult Uncinaria stenocephala), and tapeworm (Dipylidium caninum, Taenia pisiformis, and Echinococcus granulosus) infections. Credelio Quattro kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and the treatment and control of tick infestations [Amblyomma americanum (lone star tick), Dermacentor variabilis (American dog tick), Ixodes scapularis (black-legged tick), and Rhipicephalus sanguineus (brown dog tick)] for one month in dogs and puppies 8 weeks of age and older and weighing 3.3 pounds or greater.
Important Safety Information: Lotilaner, an ingredient in Credelio Quattro, belongs to the isoxazoline class and has been associated with neurologic adverse reactions like tremors, ataxia, and seizures even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. Dogs should be tested for existing heartworm infections before Credelio Quattro administration as it is not effective against adult D. immitis. The safe use in breeding, pregnant, or lactating dogs has not been evaluated. The most frequently reported adverse reactions in clinical trials were vomiting and diarrhea. For full prescribing information see the Credelio Quattro package insert.
Credelio Quattro, Elanco, and the diagonal bar logo are trademarks of Elanco or its affiliates. ©2025 Elanco or its affiliates.
From exam room tips to practice management insights, get trusted veterinary news delivered straight to your inbox—subscribe to dvm360.